ClinicalTrials.gg
CompletedNCT05388981Updated Sep 25, 2024

Study of Single Doses of SBT115301 in Healthy Participants

A Phase 1 interventional study of SBT115301 and Placebo in Safety, sponsored by Sonoma Biotherapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-25.

Sponsored by Sonoma Biotherapeutics, Inc. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Jan 2024, 2 years 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study will test the safety and effects of SBT115301 when given as a single dose to healthy adult volunteers. It is the first study being done in humans. Increasing dose levels will be given after the safety at lower dose levels is shown. Some participants will receive placebo, and neither the participants or the study staff will know what drug (SBT115301 or placebo) is being given.

02

Conditions studied

  • Safety

Keywords

  • healthy volunteers
  • safety
03

In context

Lead sponsor

Sonoma Biotherapeutics, Inc. is the lead sponsor of 4 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females not of
  • Healthy participants based on medical history, physical examination, vital signs, , and clinical laboratory tests
  • Use of highly effective methods of (sexually active males with partners of childbearing potential)
  • Up-to-date vaccinations for coronavirus disease (COVID-19) and influenza

Exclusion criteria

Exclusion Criteria:

  • Chronic or acute illness
  • History of drug or alcohol abuse or positive drug or alcohol screening results
  • abnormality
  • Received attenuated within 1 month or COVID-19 vaccine within 2 weeks prior to study, or anticipated vaccination during study period
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Intramuscular (IM) dose level 1

    Biological: SBT115301 · Biological: Placebo

  • Experimental
    Cohort 2

    IM dose level 2

    Biological: SBT115301 · Biological: Placebo

  • Experimental
    Cohort 3

    IM dose level 3

    Biological: SBT115301 · Biological: Placebo

  • Experimental
    Cohort 4

    IM dose level 4

    Biological: SBT115301 · Biological: Placebo

  • Experimental
    Cohort 5

    Intravenous (IV) dose level 1

    Biological: SBT115301 · Biological: Placebo

Interventions

  • BiologicalSBT115301

    Immunomodulatory dimeric fusion protein

  • BiologicalPlacebo

    Matched placebo

06

What researchers measure

Primary outcomes

  1. Adverse events

    Number of participants with treatment-emergent adverse events

    Time frame: Day of treatment to end of follow-up period (71 days for Cohorts 1-4; 140 days for Cohort 5)

  2. Serious adverse events

    Number of participants with serious adverse events

    Time frame: Baseline to end of follow-up period (71 days for Cohorts 1-4; 140 days for Cohort 5)

Secondary outcomes

  1. SBT115301 Serum Concentration

    Serum concentration of SBT115301

    Time frame: Day 1 to Day 72 (Cohorts 1-4) or Day 141 (Cohort 5)

  2. Pharmacokinetic Parameters: Cmax

    Maximum serum concentration (Cmax) of SBT115301

    Time frame: Day 1 to Day 72 (Cohorts 1-4) or Day 141 (Cohort 5)

  3. Pharmacokinetic Parameters: Tmax

    Time of maximum SBT115301 serum concentration (Tmax)

    Time frame: Day 1 to Day 72 (Cohorts 1-4) or Day 141 (Cohort 5)

  4. Pharmacokinetic Parameters: AUC(0-last)

    Area under the serum concentration-time curve (AUC) from time 0 to the last measurable serum concentration

    Time frame: Day 1 to Day 72 (Cohorts 1-4) or Day 141 (Cohort 5)

  5. Pharmacokinetic Parameters: AUC(0-inf)

    Area under the serum concentration-time curve from time 0 extrapolated to infinity

    Time frame: Day 1 to Day 72 (Cohorts 1-4) or Day 141 (Cohort 5)

  6. Pharmacokinetic Parameters: t1/2

    Terminal elimination half-life (t1/2)

    Time frame: Day 1 to Day 72 (Cohorts 1-4) or Day 141 (Cohort 5)

  7. Anti-Drug Antibodies

    Number of participants with anti-drug antibodies

    Time frame: Day 1 to Day 72 (Cohorts 1-4) or Day 141 (Cohort 5)

07

Study locations

1 site
  • Celerion
    Tempe, Arizona 85283, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2022 to primary completion in Jan 2024, 17 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2022
First posted
May 24, 2022
StartActual
Jul 25, 2022
Primary completionActual
Jan 3, 2024
CompletionActual
Jan 3, 2024
Last update
Sep 25, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05388981
Lead sponsor
Sonoma Biotherapeutics, Inc.
Responsible party
Sponsor
First posted
May 24, 2022
Start date
Jul 25, 2022
Primary completion
Jan 3, 2024
Completion
Jan 3, 2024
Last update
Sep 25, 2024

Study contacts

Michelle Valentine, DO
principal investigator · Celerion

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion